TrialJournal of neuro-oncology2019

A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.

Jiayi Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.